Xiaofeng Zhang

Xiaofeng Zhang

Auto-generated profile, based on publicly available information

Xiaofeng Zhang

Department of Gastroenterology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
JYJianfeng Yang
Jianfeng Yang
JWJing Wang
Jing Wang
HZHaibin Zhou
Haibin Zhou
YWYucheng Wang
Yucheng Wang
HHHaitao Huang
Haitao Huang
XZXiaofeng Zhang
Xiaofeng Zhang

1 December 2016 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
JYJianfeng Yang
Jianfeng Yang
HSHongzhang Shen
Hongzhang Shen
HJHangbin Jin
Hangbin Jin
QLQifeng Lou
Qifeng Lou
XZXiaofeng Zhang
Xiaofeng Zhang

16 May 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
WGWeigang Gu
Weigang Gu
HSHongZhang Shen
HongZhang Shen
LXLu Xie
Lu Xie
XZXiaofeng Zhang
Xiaofeng Zhang
JYJianfeng Yang
Jianfeng Yang
Pancreatic cancer is the leading cause of cancer-related deaths worldwide, with limited treatment options and low long-term survival rates. The complex and variable signal regulation networks are one of the important reasons why it is difficult for pancreatic cancer to develop precise targeted therapy drugs. Numerous studies have associated feedback loop regulation with the development and therapeutic response of cancers including pancreatic cancer. Therefore, we review researches on the role of feedback loops in the progression of pancreatic cancer, and summarize the connection between feedback loops and several signaling pathways in pancreatic cancer, as well as recent advances in the intervention of feedback loops in pancreatic cancer treatment, highlighting the potential of capitalizing on feedback loops modulation in targeted therapy for pancreatic cancer.

1 January 2021 in Endoscopic Ultrasound
Verified
Journal Article
Open access
JYJianfeng Yang
Jianfeng Yang
XZXiaofeng Zhang
Xiaofeng Zhang
JJJieling Jiang
Jieling Jiang
QLQifeng Lou
Qifeng Lou
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society

15 April 2025 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
MSMin-Hui Sun
Min-Hui Sun
HSHong-Zhang Shen
Hong-Zhang Shen
HJHang-Bin Jin
Hang-Bin Jin
JYJian-Feng Yang
Jian-Feng Yang
XZXiao-Feng Zhang
Xiao-Feng Zhang
BACKGROUND Palliative care for unresectable pancreatic cancer (PC) focuses mainly on the symptoms of the disease, including abdominal pain, obstructive jaundice, and malnutrition. Biliary stent placement using endoscopic retrograde cholangiopancreatography (ERCP) to relieve biliary obstruction has become an internationally recognized treatment. Although a few studies have evaluated the efficacy of endoscopic pancreatic duct stenting in advanced PC, no consensus exists on the use of endoscopic treatment to relieve pain and improve nutritional status. AIM To evaluate the efficacy and safety of early pancreatic duct stenting in patients with unresectable PC. METHODS Patients with unresectable PC were recruited. The participants were randomized into two groups: The double-stent group underwent ERCP with a fully-covered self-expandable metallic biliary stent (FCSEMS) and a pancreatic duct stent, while the single-stent group underwent ERCP with an FCSEMS only. Abdominal pain, nutritional status, and incidence of adverse events were compared between the two groups using the SPSS software. RESULTS Seventy-eight patients with unresectable PC were included in the analysis (40 and 38 in the double- and single-stent groups, respectively). The median pain scores of patients in the double-stent group were lower than those in the single-stent group at 1 (0 vs 2.5, P = 0.002), 2 (0 vs 3, P < 0.001), 3 (0 vs 4, P < 0.001), and 6 months (0 vs 4, P < 0.001) after ERCP. Total serum protein levels in patients in the double-stent group were higher than those in the single-stent group (66.6 ± 8.4 g/L vs 60.4 ± 4.0 g/L, P = 0.046) 6 months postoperatively. The body mass index (BMI) of patients in both groups decreased at six months. However, the BMI in the single-stent group was higher than that in the double-stent group (P < 0.001). CONCLUSION Early pancreatic duct stenting reduces abdominal pain and improves nutritional status in patients with unresectable PC without reducing the technical success rate or increasing the incidence of adverse events.